Virtual Library

Start Your Search

Kohei Okafuji



Author of

  • +

    P2.04 - Immunooncology (Not CME Accredited Session) (ID 953)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.04-16 - Correlation Between Programmed Death Ligand 1(PD-L1) Expression and Solid Component on HRCT in Stage I Lung Cancer Patients (ID 13113)

      16:45 - 18:00  |  Author(s): Kohei Okafuji

      • Abstract

      Background

      Programmed death ligand 1(PD-L1) expression on lung cancer cell is one of the predictors of treatment response to immune checkpoint inhibitors. However, little has been reported about PD-L1 expression in patients with early stage lung cancer because previous clinical trials were mostly focused on advanced stage, and little has been also reported about association PD-L1 expression with high-resolution computed tomography (HRCT) findings. The purposes of this study were to describe PD-L1 expression in early stage lung cancer and to evaluate correlation with solid component on HRCT.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We evaluated patients with non-small cell lung carcinoma (NSCLC) who had been performed surgical resection between March 2017 and 2018, and resulted in pathological stage were stage I. Adenocarcinoma in situ was excluded. PD-L1 expression was assessed by means of the PD-L1 immunohistochemistry(IHC) 22C3 pharmDx assay (Agilent). PD-L1 expression was classified into three categories, negative group (PD-L1 expression less than 1%), low expression group (over 1% and less than 50%) and high expression group (over 50%). We also described HRCT findings of the tumor by solid/ground glass nodule (GGN)-ratio, calculating by the ratio of the solid component and GGN component area. The ratio was defined 0% in pure GGN cases and 100% in solid nodule cases.

      4c3880bb027f159e801041b1021e88e8 Result

      During study period, 60 patients were evaluated. The mean age (±SD) was 67 (±10) years old, 28 patients (46.7%) were female. 47 patients (78.3%) were adenocarcinoma and, of these, 10 patients were minimally invasive adenocarcinoma. In radiological classification, 8 patients (13.3%) were pure GGN, 24 (40.0%) were part solid nodules and 28 (46.7%) were solid nodules. In PD-L1 expression, 33 (55.0%) patients were negative group, 23 (38.3%) were low expression group and 4 (6.7%) were high expression group. The mean PD-L1 expression (±SD) was 7.82 (±18.6)% and the mean solid/GGN-ratio (±SD) was 58.8 (±40.9)%. A Spearman’s correlation test showed significant correlation between PD-L1 expression and solid/GGN-ratio. (rho=0.43, p<0.001)

      8eea62084ca7e541d918e823422bd82e Conclusion

      There was a positive correlation between PD-L1 expression and solid component on HRCT in stage I NSCLC patients.

      6f8b794f3246b0c1e1780bb4d4d5dc53